Effect of propranolol in the retinal tumours of patients with von Hippel-Lindau disease

Therapeutic effect of propranolol in a series of patients with von Hippel-Lindau disease and retinal hemangioblastomas in short, medium and long term treatment.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-003671-30-ES

Enrollment

Unknown

Registered

2014-09-22

Start date

2014-10-31

Completion date

Unknown

Last updated

2016-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

VON HIPPEL-LINDAU DISEASE

Interventions

Trade Name: SUMIAL 40 mg COMPRIMIDOS RECUBIERTOS CON PELICULA Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PROPRANOLOL CAS Number: 525-66-6 Current Sponsor code: PROPRA Other descripti

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: PATIENTS DIAGNOSED OF VON HIPPEL-LINDAU DISEASE AND RETINAL HEMANGIOBLASTOMAS, THAT IN ADDITION: - AT LEAST ONE PAPILLARY OR JUXTAPAPILLARY HB, OR - PERIPHERICAL HB, WHO HAD REJECTED ANOTHER TREATMENTS Are the trial subjects under 18? yes Number of subjects for this age range: 1 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 9 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: CONTRAINDICATIONS TO TAKE PROPRANOLOL

Design outcomes

Primary

Measure	Time frame
Main Objective: TO EVALUATE THE EFFECTIVENESS OF PROPRANOLOL IN CONTROLLING THE GROWTH OF PAPILLARY AND JUXTAPAPILLARY RETINAL HEMANGIOBLASTOMAS (HB);Secondary Objective: TO DETERMINE IF PROPRANOLOL HAS A POSITIVE EFFECT IN CONTROLLING THE GROWTH OF CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS;Primary end point(s): NUMBER AND SIZE OF THE RETINAL HEMANGIOBLASTOMAS;Timepoint(s) of evaluation of this end point: EVALUATION AT 1-3-6-9-12 MONTHS	—

Measure

Time frame

Main Objective: TO EVALUATE THE EFFECTIVENESS OF PROPRANOLOL IN CONTROLLING THE GROWTH OF PAPILLARY AND JUXTAPAPILLARY RETINAL HEMANGIOBLASTOMAS (HB);Secondary Objective: TO DETERMINE IF PROPRANOLOL HAS A POSITIVE EFFECT IN CONTROLLING THE GROWTH OF CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS;Primary end point(s): NUMBER AND SIZE OF THE RETINAL HEMANGIOBLASTOMAS;Timepoint(s) of evaluation of this end point: EVALUATION AT 1-3-6-9-12 MONTHS

—

Secondary

Measure	Time frame
Secondary end point(s): NUMBER AND SIZE OF THE CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS;Timepoint(s) of evaluation of this end point: 12 MONTHS SINCE THE START OF TREATMENT	—

Countries

Spain

Contacts

Public ContactALIANZA VHL

ALIANZA ESPAÑOLA DE FAMILIAS DE VON HIPPEL-LINDAU

INFO@ALIANZAVHL.ORG34607680759

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026